Foghorn Therapeutics Inc. (FHTX) is a Healthcare stock trading at $4.17 (as of 2026-06-18), with a market capitalization of $251.30M and a trailing P/E of -3.5. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.
Foghorn Therapeutics Inc. is a biopharmaceutical company developing small-molecule therapies that modulate genetically determined chromatin regulatory dependencies, including inhibitors and protein degraders targeting BRG1/BRM, BRD9, and other chromatin regulators such as BRM and ARID1B. Its programs are aimed at treating metastatic uveal melanoma, relapsed/refractory acute myeloid leukemia and myelodysplastic syndrome, and certain cancers including synovial sarcoma and ovarian, endometrial, colorectal, bladder, and gastric cancers.